Royalty Pharma plc
RPRX
$30.38
-$0.73-2.35%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -24.31% | 520.96% | 164.07% | 140.75% | 2,549.50% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -4.57% | -9.01% | -12.01% | -8.50% | -4.01% |
| Total Other Non-Cash Items | 16.59% | -163.06% | -57.49% | -44.37% | -195.06% |
| Change in Net Operating Assets | -5.30% | -3.12% | -5.22% | -8.24% | 26.26% |
| Cash from Operations | -7.32% | 0.50% | -2.96% | -3.64% | 39.36% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.20% | -382.26% | -48.90% | -0.11% | -101.35% |
| Cash from Investing | -29.20% | -382.26% | -48.90% | -0.11% | -101.35% |
| Total Debt Issued | 320.35% | -- | -- | -- | -- |
| Total Debt Repaid | -- | 65.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 24.65% | 24.52% | -86.19% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -5.06% | -5.37% | -5.93% | -7.01% | -7.50% |
| Other Financing Activities | -3.77% | 9.02% | 12.51% | 18.91% | 20.58% |
| Cash from Financing | 116.81% | 117.74% | 38.58% | -130.17% | -127.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 136.64% | 124.65% | -727.97% | -715.02% | -827.00% |
